Leuviora Organic Gymnema is promoted for sugar cravings, blood glucose management and pancreatic beta-cell support. Its advertising combines botanical research, customer testimonials and medical illustrations to suggest that a daily capsule can support the cells responsible for producing insulin.

Gymnema sylvestre is a real medicinal plant with a history of research. The question for consumers is whether the evidence supports this particular supplement and the expectations created by its marketing. How we reviewed it: This is a desk-based consumer review of the seller’s website, supplied promotional images, published research and purchase policies. It does not include hands-on use, laboratory analysis, delivery testing or a trial of the refund process. Ingredient amounts and certification statements are the seller’s claims unless otherwise stated. This article is general information, not personalised medical advice. No affiliate links to Leuviora are included.

What is in Leuviora Organic Gymnema?

The supplied Supplement Facts image describes one capsule per serving and 30 servings per bottle. Its advertised composition is:

Disclosing the powder, extract and standardisation is useful. However, 700 mg of combined plant material is not equivalent to 700 mg of concentrated extract. This matters when the marketing compares its dose with research using different Gymnema preparations.

The advertising also discusses Conduritol A, a constituent of Gymnema. The panel does not state how much Conduritol A the capsule contains. That limits any comparison with studies investigating the isolated compound.

What does the research actually show?

Sugar cravings and sweet-taste perception

There is human evidence that certain Gymnema preparations can temporarily reduce the appeal of sweet foods. A 2025 study involving 32 healthy participants investigated Gymnema-containing mints and reported improvements in some measures of cravings and sweet-food consumption.

The delivery method is important. A mint exposes the tongue directly to the ingredient. A swallowed capsule does not provide the same direct exposure. Our assessment is that the mint study cannot establish that Leuviora produces the immediate taste-blocking effect suggested by its advertising.

Blood glucose and HbA1c

A 2021 systematic review and meta-analysis combined 10 studies involving 419 participants and reported improvements in blood glucose and HbA1c, a measure of average glucose over the preceding months.

However, the pooled analysis compared post-treatment measurements with baseline, and the results varied substantially between studies. Those limitations reduce confidence about how much benefit Gymnema itself caused. Consistent results from larger, well-controlled trials would provide stronger evidence.

The review supports further investigation of Gymnema. It does not establish that Leuviora’s capsule delivers the same results or prevents diabetes complications.

The 130.3% beta-cell finding

The striking figure in Leuviora’s marketing can be traced to a 2015 paper by Violet Kasabri and colleagues. The researchers studied aqueous Gymnema extracts and laboratory-grown MIN6 pancreatic beta cells, reporting increased cell expansion under specific experimental conditions.

This is a laboratory finding. It does not demonstrate that a person taking Leuviora will grow new pancreatic beta cells, restore normal insulin production or achieve a predictable reduction in HbA1c. The concentration reaching cells in an experiment also cannot simply be equated with the milligrams printed on a capsule label.

Conduritol A and pancreatic cells

A 2008 animal study by Wei and colleagues investigated Conduritol A in chemically induced diabetes. After 14 days, treated groups showed improvements in several measures, including higher pancreatic beta-cell counts than the untreated diabetic comparison group.

That provides a basis for saying the compound has been studied in animals. It does not establish pancreatic regeneration in people. A higher cell count at an experimental endpoint also cannot, by itself, distinguish preservation of existing cells from production of new cells.

With no stated Conduritol A quantity in the supplied product panel, the connection between that experiment and this capsule remains uncertain.

A scientific reference in the advertising does not check out

The supplied graphic headed “Backed By 30+ Years of Scientific Research” attributes the 130.3% finding to K. Nakamura and colleagues in Cell Biology International. Those details do not match the paper reporting the result.

The actual paper’s DOI is 10.9734/BJMMR/2015/12681. Pages 782–789 of Cell Biology International, volume 38, instead belong to an unrelated paper about retinoic acid and mouse bone-marrow-derived cells, in issue 6.

This is a material credibility concern. Consumers should be able to locate the research used to persuade them to buy a health product. The error does not prove that every claim is false, but this graphic is unreliable as a scientific reference.

PubMed is a literature-search resource. Displaying its name or a publisher’s logo does not demonstrate that the organisation has endorsed the supplement.

How convincing are the wider marketing claims?

The advertising gives substantial attention to pancreas support and presents Leuviora as addressing the source of glucose problems. It also compares the product favourably with berberine, cinnamon and other Gymnema supplements.

We did not find a comparative clinical trial supplied to substantiate those superiority claims. A proposed mechanism is not enough to show that one finished product works better than another.

The assertion that Gymnema requires at least 400 mg daily is also too broad for the evidence presented. Different extracts and plant powders contain different quantities of active compounds. Adding their weights together does not demonstrate equivalence to a studied preparation.

Similarly, the advertised sequence of early taste changes followed by more stable glucose readings is not an established treatment timetable for Leuviora. Testimonials and customer surveys cannot isolate the effects of a capsule from changes in diet, medicines, activity or other influences.

The seller displays a 4.9 rating and a large customer total. We could not independently authenticate those figures. We also found no accompanying methodology sufficient to treat its customer-result percentages as clinical success rates.

Quality claims and seller transparency

The seller advertises organic ingredients, Non-GMO verification and independent testing. We did not locate a publicly accessible batch-specific certificate of analysis or documentation sufficient to authenticate the advertised certifications. These claims remain unverified in this review.

Useful evidence would include the testing laboratory’s identity, the product and batch tested, dated results for ingredient identity and potency, and relevant contaminant results. Manufacturing and agricultural certifications would not, by themselves, establish effectiveness for diabetes.

The terms of service reviewed still contained unfilled placeholders for the business address, phone number and registration details. That leaves consumers with incomplete information about the entity responsible for the product.

Price, subscriptions and the refund guarantee

The product page retrieved displayed a US$42.65 price, while another offer section displayed $46.50. Treat these as advertised figures rather than a verified Australian checkout total. Confirm the currency, delivery charges and whether the selected offer involves recurring billing.

The 60-day money-back promotion also needs clarification. The written refund policy requires items to be unused and in their original condition, and excludes sale items.

Those conditions appear inconsistent with trying a discounted supplement and returning it because it did not help. Before relying on the guarantee, obtain written confirmation that an opened bottle and a promotional purchase qualify, together with the return address and any costs.

Is Gymnema safe to take with diabetes medication?

Gymnema should not be treated as risk-free because it is plant-derived. A risk assessment published in the EFSA Journal identified concerns about combining certain Gymnema preparations with diabetes medicines, including the possibility of enhanced glucose-lowering effects.

People taking insulin or other glucose-lowering medicines, or experiencing low glucose readings, should discuss the supplement with their pharmacist or diabetes clinician before use. Do not independently reduce or stop prescribed treatment to try it.

LiverTox also records rare reports of suspected liver injury involving Gymnema products, while noting that attribution to the herb has often been uncertain. These reports do not establish that Leuviora causes liver injury, but they argue against blanket safety assurances.

The US National Center for Complementary and Integrative Health advises against replacing established diabetes treatment with an unproven supplement.

What should Australian buyers check?

We could not verify Leuviora’s Australian regulatory status from the material reviewed. Ask for its exact Australian Register of Therapeutic Goods entry and AUST number, if applicable, and identify the Australian sponsor responsible for it.

The TGA explains that AUST L medicines are not assessed for efficacy, whereas AUST L(A) and AUST R medicines are. Some lawful access pathways involve products without an AUST number, so the absence of a number in advertising alone is not a determination that a product is illegally supplied.

Our verdict on Leuviora Organic Gymnema

The disclosed formula is straightforward, and there is enough research on Gymnema to make it an interesting subject for further study. Those are reasonable positives.

However, the evidence does not establish the advertised benefits of the finished Leuviora capsule. The inaccurate research citation, weak dose comparisons, incomplete business details and conflicting guarantee conditions make the purchase difficult to recommend.

Our recommendation is to hold off purchasing. Confidence would require reliable product-specific evidence or a convincing demonstration of equivalence to studied preparations, independently verifiable quality documentation, accurate scientific references and clear customer terms. Anyone considering Gymnema for blood glucose management should discuss it with a healthcare professional first.

Sources and review materials

1. Leuviora
   product page,
   pancreas education page,
   supplied promotional images,
   terms
   and
   refund policy,
   reviewed 30 September 2026.
2. Hsiao WH et al.
   The effect of a 14-day Gymnema sylvestre intervention to reduce sugar intake in people self-identifying with a sweet tooth.
   Appetite, 2025. DOI: 10.1016/j.appet.2025.107871.
3. Devangan S et al.
   Systematic review and meta-analysis of Gymnema supplementation and glycaemic control,
   2021.
4. Kasabri V et al.
   Laboratory study of Gymnema extracts and MIN6 beta-cell proliferation,
   2015;7(3):180–194. DOI: 10.9734/BJMMR/2015/12681.
5. Kashani IR et al.
   Retinoic acid and bone-marrow-derived cells.
   Cell Biology International, 2014;38(6):782–789.
   Used to check the advertisement’s bibliographic details, not as evidence about Gymnema.
6. Wei JH et al.
   Experimental study of the hypoglycaemic activity of Conduritol A from Gymnema stems,
   2008. PMID: 19294862.
7. Marakis G et al.
   Risk assessment of Gymnema sylvestre used in food supplements.
   EFSA Journal, 2018.
8. National Institute of Diabetes and Digestive and Kidney Diseases.
   LiverTox: Gymnema,
   updated 28 October 2024.
9. NCCIH.
   Diabetes and dietary supplements.
10. TGA.
    AUST numbers on medicine labels.

Website claims, prices and policies can change. The findings above relate to the material reviewed on the stated date. This review does not determine the contents of an individual bottle or the authenticity of every customer testimonial.